Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.
| Revenue (TTM) | $18.06M |
| Gross Profit (TTM) | $18.06M |
| EBITDA | $-21.65M |
| Operating Margin | -44.20% |
| Return on Equity | -20.20% |
| Return on Assets | -8.70% |
| Revenue/Share (TTM) | $0.45 |
| Book Value | $3.34 |
| Price-to-Book | 4.71 |
| Price-to-Sales (TTM) | 39.34 |
| EV/Revenue | 44.65 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 178.10% |
| Shares Outstanding | $58.73M |
| Float | $49.57M |
| % Insiders | 0.94% |
| % Institutions | 41.33% |
Volatility is currently expanding
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial
Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-May-Proceed" letter SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd.
The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL).
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J.
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both QD and QW arms are now enrolling SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ANL and any ticker you trade — then tracks every position and per-strategy win rate.
